DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Recommendation of “Hold” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have earned an average recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company.

A number of analysts have issued reports on the company. BNP Paribas Exane downgraded DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Piper Sandler started coverage on DiaSorin in a research report on Thursday, June 11th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. Zacks Research raised shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Finally, UBS Group cut shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th.

DiaSorin Stock Down 3.0%

Shares of OTCMKTS:DSRLF opened at $77.60 on Tuesday. The stock’s 50-day moving average is $77.55 and its 200-day moving average is $76.52. DiaSorin has a 52-week low of $66.50 and a 52-week high of $100.00.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.